CDTX: Cidara Therapeutics Corp Market Cap to Revenue

Symbol and logo of brand Cidara Therapeutics Corp (CDTX)

Cidara Therapeutics (CDTX) attracts leading immunologists through flexible terms and options, as reflected in this chart. The price-to-sales ratio illustrates the market reaction, where the value of 4588.60 reflects the metric's balance. The business foundation is built upon the protected Cloudbreak platform and strict FDA oversight, while stability is ensured by contract capacities that are systematically adapted for the release of new therapeutic compounds.

Cidara Therapeutics Inc (CDTX): P/S Multiple from 07/04/2022 to 08/09/2025

Metric breakdowns and analytics for Cidara Therapeutics Corp (CDTX)

- price and consensus price forecast:
Market Chart Cidara Therapeutics, Inc.|CDTX - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Cidara Therapeutics Corp|CDTX - Enterprise Value
- book value of equity indicators:
Net Assets per Share Cidara|CDTX - Book Capitalization|Capitalization to Book Value Ratio cidara.com|CDTX - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Cidara Therapeutics|CDTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Cidara Corp|CDTX - Company Aggregate Debts|Debts to Book Capitalization Cidara Therapeutics Corp|CDTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Cidara|Intermediate Liquidity Ratio cidara.com
- net income and valuation ratios data:
CDTX - Net Profit|Expected Net Income Cidara Therapeutics|CDTX - P/E Multiple|Projected Price to Earnings Ratio Cidara|CDTX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cidara Therapeutics Corp|CDTX - Operating profit EBITDA|Net earnings per share (EPS TTM) Cidara|CDTX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cidara.com|CDTX - Earnings growth in current year|Expected net earnings per share growth next year Cidara Therapeutics
- issuer revenue and sales details:
CDTX - Company Sales|Projected Sales Volume Cidara Therapeutics Corp|CDTX - Market Cap to Revenue|Price to Expected Revenue Ratio Cidara Therapeutics Corp
General company analysis:CDTX cidara.com
Signature product of Cidara Therapeutics Corp

This metric reflects the ratio of the market capitalization of Cidara Therapeutics (CDTX) to its annual sales volume, allowing for an objective valuation of each dollar of revenue while filtering out market noise. Analyzing the price-to-sales ratio helps identify the risks of overpaying for the asset amid high capital burn and uncertainty regarding the outcomes of clinical trials for new antibiotics.

Who Cidara Therapeutics competes with

Price-to-Revenue Coefficient gilead.com|P/S Multiple NVAX (Novavax)|CVAC - Market Cap to Revenue|Valneva Pharma - P/S Multiple|Price-to-Revenue Coefficient Vir Corp VIR|SIGA: P/S Multiple|Market Cap to Revenue Ratio EBS|AVIR (Atea Pharmaceuticals, Inc.) - P/S Multiple|P/S Multiple Invivyd Corp|Price-to-Revenue Ratio Enanta (ENTA)|INO (Inovio Pharma) - Market Capitalization-to-Revenue Ratio|P/S Multiple HLVX (HilleVax, Inc.)|P/S Multiple kalaristx.com KLRS|DYAI: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NNVC (NanoViricides, Inc.)|TLPH (Talphera Corp) - Market Cap to Revenue|COCP: Market Cap to Sales Volume|TRAW (Traws Pharma Inc) - P/S Multiple|DWTX: Market Capitalization-to-Revenue Ratio|P/S Multiple QLGN|ALVR - Price to Sales|Price-to-Revenue Ratio VBI Vaccines VBIV|Market Capitalization-to-Revenue Ratio VIRI|Vaxart Corp - P/S Multiple